Palo Alto Networks Inc Logo
GB00BZ1BLL44
A2DH40
CREO.L

Palo Alto Networks Inc

Loading quotes...

Forecast

There is no analyst data available for this company.


  • Palo Alto Networks: Arora sees AI as driver of platform strategy and warns of early risks

    At the Goldman Sachs conference, Palo Alto Networks emphasized that AI will significantly increase data volumes, security spending and demand for platform providers. CEO Nikesh Arora cited company size, data collection and product breadth as competitive advantages, but said AI security is still immature, costly on endpoint devices and largely untapped in the market. Products like Prisma AIRS and Mithos are already contributing revenue and vulnerability detection, while the company is pursuing a multi-model architecture (small models at the edge, frontier models in the cloud) to improve economics. The stock closed slightly up, and Palo Alto Networks sees major opportunities from consolidation and rising AI investments. » More on de.investing.com


  • Palo Alto Networks faces high bar after CrowdStrike rally ahead of Q4 results

    CrowdStrike's strong quarter and raised guidance have lifted cybersecurity sentiment, but Palo Alto Networks must validate the rally when it reports fiscal Q4 results. Management's guidance targets roughly 32% revenue growth and next-generation security ARR of $8.9–8.95 billion, while investors will watch organic NGS ARR (about 28%) as the clearest signal of underlying momentum. History of post-earnings selloffs despite beats and current valuation/options positioning suggest a sizable downside risk if Palo Alto's execution or fiscal 2027 framing falls short. » More on finance.yahoo.com

Financials

In the last quarter, Palo Alto Networks Inc had revenue of €3.71M and net profit of -€8.36M
(EUR) June 2026
YoY
Revenue 3.71M -
Gross profit 1.28M -
Net profit -8.36M -
EBITDA -8.82M -

Fundamentals

Metric Value
Market capitalization
€60.32M
Number of shares
449.14M
52-week high/low
€0.22 - €0.11
Dividends No
Beta
1.56
P/E ratio
-2.48
PEG ratio
0.01
P/B ratio
0.98
P/S ratio
7.22

Company profile

Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Croma, an energy platform that powers a suite of multi-modal devices to optimize treatments for patients and physicians. The company also offers Speedboat Inject, an energy multimodality instrument for flexible endoscopy; Speedboat Slim, a flexible bipolar RF and microwave device for cutting and coagulation; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; and SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highlyperfused tissues. Creo Medical Limited was formerly known as MicroOncology Ltd. The company was incorporated in 2003 and is headquartered in Chepstow, the United Kingdom. Creo Medical Limited is a subsidiary of Creo Medical Group plc.

Name
Palo Alto Networks Inc
CEO
Craig Jonathan Gulliford
Headquarters Chepstow, wa
United Kingdom
Website
IPO
12/09/2016
Employees 104

Ticker symbols

Exchange Symbol
London Stock Exchange
CREO.L
Frankfurt
1RC.F
London
CREO.L
🍪

Parqet  uses cookies. Learn more